REG - Fragrant Prosperity - Notice of AGM
16/12/2021 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211216:nRSP8327Va&default-theme=true
RNS Number : 8327V Fragrant Prosperity Holdings Ltd 16 December 2021
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN,
INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA,
THE REPUBLIC OF IRELAND OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH
PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
Fragrant Prosperity Holdings Limited
("FPP" or the "Company")
Notice of AGM
7.00am 16 December 2021
The Company announces that it has posted a Notice of Annual General Meeting
("AGM") to Shareholders, a copy of which is available on the Company's website
https://www.fragrantprosperityholdings.com/ the AGM will be held at the
offices of Hill Dickinson LLP, The Broadgate Tower, 20 Primrose St, London
EC2A 2EW at 10 a.m. GMT on 13 January 2022. Extracts of the Notice of AGM are
set out in Appendix A below.
This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014 which is part of UK law by virtue of the European
Union (Withdrawal) Act 2018. Upon the publication of this announcement this
information is considered to be in the public domain.
- Ends -
Enquiries
Fragrant Prosperity Holdings Limited +44 (0)20 3137 1902
Simon Retter
Optiva Securities - Broker to FPP +44 (0)20 3137 1903
Vishal Balasingham
Appendix A
Note: All terms referenced below are as defined in the Notice of AGM
Dear Shareholder,
This letter gives details of the business to be transacted at the 2021 Annual
General Meeting of Fragrant Prosperity Holdings Limited ("FPP" or the
"Company") to be held at Hill Dickinson LLP, The Broadgate Tower, 20 Primrose
St, London EC2A 2EW at 10 a.m. GMT on 13 January 2022 (the "AGM").
Introduction to the Proposals
On 24 May 2021 the Company announced ("Announcement") that it had signed a
letter of intent ("LOI") with CiiTECH Ltd ("CiiTECH" or the "Target"), a
leading cannabis wellness company based in the UK and Israel, in relation to
the potential acquisition of the entire issued share capital of the Target by
FPP ("Intended Acquisition"). Although the exclusivity period under the LOI
has expired the Company is still working with CiiTECH towards signing
definitive agreements in respect of the Intended Acquisition. A summary of
CiiTECH's business is contained in Appendix 1.
The Intended Acquisition constitutes a reverse takeover for the purposes of
Listing Rule 5.6 and so the Company is obliged to apply for readmission of its
Ordinary Shares to the Official List of the Financial Conduct Authority
("FCA") ("Admission"). Under the requirements of the Prospectus Regulation,
the Company is therefore required to publish a FCA approved prospectus
("Prospectus") in order for its Ordinary Shares to be re-admitted to the
Official List of the FCA. The Company is the process of having a prospectus
approved by the FCA but there is currently no certainty that the FCA will
approve the Prospectus. If the FCA does not approve the Prospectus then the
Intended Acquisition will not proceed.
The Company plans to raise additional equity capital to fund the development
of the business of CiiTECH through a placing of new shares in the Company by
Optiva Securities Limited who are collaborating with Chrystal Capital LLP
("Placing") to raise approximately £3 million ("Target Amount"). The
Company is aiming for the Placing to occur at the same time as Admission which
will be immediately following the completion of the Intended Acquisition if it
proceeds.
The price of the Intended Acquisition is subject to final agreement with
CiiTECH and shall comprise of 333,333,333 ordinary shares in the capital of
the Company ("Ordinary Shares") for CiiTECH's current equity and further
Ordinary Shares to be issued in exchange for shares in CiiTECH that will be
issued pursuant to conversion £2,2721,000 of convertible loan notes issued by
CiiTECH ("Convertible Loan Notes"). The price of the Intended Acquisition is
predominantly dependent upon the results of the Placing because it is proposed
that this price shall be payable in Ordinary Shares. The Ordinary Shares
will be issued to the owners of CiiTECH as consideration for the Intended
Acquisition at the same price as the Ordinary Shares issued pursuant to the
Placing.
It is currently anticipated that the Placing will be conducted at a price of
between 2 and 3.85p per Ordinary Share ("Proposed Issue Price"). This gives
CiiTECH a valuation (including the Convertible Loan Notes) of between
£9,667,944 and £15,834,610 ("Proposed Purchase Price") assuming a Placing of
£3 million of new Ordinary Shares. These figures are lower than those
announced on 24 May 2021 as the current feedback from market participants
indicates that this a more realistic price range in current market conditions,
which have been challenging for the cannabis sector and reflects, to a large
extent, the decline in share prices of a number of listed peers in the time
from announcing the Intended Acquisition in May 2021 to today.
The Company is currently registered in the British Virgin Islands. The laws
of the British Virgin Islands currently prohibit the Company from receiving
funds from CiiTECH or using the Company's cash to fund CiiTECH's cannabis
related activities. Therefore, the board of the Company (Board) are
proposing that the Company be redomiciled from the British Virgin Islands to
Guernsey ("Re-domiciliation") where the laws in respect of the proceeds of
CiiTECH's business are clearer. A summary of the key elements of Guernsey
corporate law are contained in Appendix 2.
If the Re-domiciliation is approved there are a few resulting consequences for
the Company. These include (i) the Company needing to change its registered
office to Guernsey, (ii) the Company adopting new articles of incorporation
("New Articles"), (iii) the Company's depositary interest facility being no
longer required, as the Ordinary Shares will be eligible for electronic
settlement in CREST. Accordingly, the agreement by which Computershare
Investor Services PLC was appointed to act as depositary services provider
will be terminated and the depositary interests cancelled and (iv) the Company
becoming subject to the Takeover Code ("Takeover Code"). In respect of the
adoption of New Articles a summary of material differences between and the
Company's existing articles ("Current Articles") and the New Articles are
contained in Appendix 3 to this notice and a copy of the New Articles are
contained in Appendix 4.
Approval of Intended Acquisition
Although there is no certainty that the Intended Acquisition will proceed and
there is no express requirement under the Company's Current Articles or the
FCA's Listing Rules to obtain shareholder approval of the Intended
Acquisition, the Board have decided to seek shareholder approval of the
Intended Acquisition at the AGM. The marketing of the Placing has not yet
completed and so there is no certainty what the Proposed Purchase Price for
the Intended Acquisition will be or what the Proposed Issue Price for Intended
Acquisition will be. Therefore, the approval the Company is seeking is based
on the maximum value for the Intended Acquisition and an anticipated fundraise
of £3 million (i.e. an issue price of 3.85p per Ordinary Share) in connection
with the Intended Acquisition.
Board Recommendation
The Company has invested a significant amount of management time and Company
resources in the Intended Acquisition. The release of the FCA Technical Note
104.1 in July 2021 during the reverse takeover process raised the bar that
cannabis companies were required to meet to admit their shares to the Official
List. This has, in part, caused the delay of the proposed Intended
Acquisition. The Board has considered the terms of the Intended Acquisition
and believes it to be in the best interests of shareholders and therefore
unanimously recommends that Shareholders vote in favour of the Resolutions at
the Annual General Meeting.
Shareholders should be aware that if Resolutions 7, 8, 10, 11, 12 or 13 are
not passed at the Annual General Meeting, it is highly likely the Intended
Acquisition would not proceed. The Company would then need to locate another
potential reverse takeover transaction. However, due to the Company's
relatively modest cash reserves and costs already incurred in relation to the
Intended Acquisition, the Director's believe that the Company would need more
capital in order to cover the costs of another transaction. The Company
would therefore either need to raise new capital or, if new capital cannot be
located, the Board would need to consider whether the Company would need to
cease trading. In these circumstances it is highly likely that any new
capital raised would be at a level below the current range of the Proposed
Issue Price as the Company would have a low net asset value and no potential
transaction. In this scenario it is highly likely that shareholders would
experience significant dilution. Therefore, shareholders are recommended to
vote in favour of the Resolutions.
Concert Party and Takeover Code
Although the Company is not currently subject to the Takeover Code, after the
Re-domiciliation it will be subject to the Takeover Code. Section 3(a) of the
Introduction to the Takeover Code provides that a company with its registered
office in the Channel Islands and whose securities are admitted to trading on
a UK regulated market (such as the Main Market) is subject to the Takeover
Code. Accordingly, following the Re-domiciliation, the Company will be subject
to the Takeover Code as its registered office will be in Guernsey and the
Company's Ordinary Shares will be admitted to the Main Market. The Takeover
Code governs, inter alia, transactions which may result in a change of control
of a public company to which the Takeover Code applies.
Under Rule 9 of the Takeover Code, when (i) any person acquires, whether by a
series of transactions over a period of time or not, an interest in shares
which, taken together with shares in which persons acting in concert with him
are interested, carry 30 per cent. or more of the voting rights of a company
subject to the Takeover Code or (ii) any person, together with persons acting
in concert with him, is interested in shares which in aggregate carry not less
than 30 per cent. of the voting rights of such a company but does not hold
shares carrying more than 50 per cent. of such voting rights, and such person,
or any person acting in concert with him, acquires an interest in any other
shares which increases the percentage of shares carrying voting rights in
which he is interested, then such person is normally required to make a
general offer to all the holders of any class of equity share capital or other
class of transferable securities carrying voting rights of that company to
acquire the balance of their interests in the company. An offer under Rule 9
of the Takeover Code must be in cash (or with a cash alternative) and must be
at not less than the highest price paid within the preceding 12 months for any
shares in the company by the person required to make the offer or any person
acting in concert with him.
The Takeover Code includes a definition of "acting in concert". Paragraph 9
of that definition makes clear that shareholders in a private company (such as
CiiTECH) who sell their shares in that company in consideration for the issue
of new shares in a company to which the Code applies will be presumed to be
persons acting in concert with other persons in the same category unless the
contrary is established. The Company has agreed with the Takeover Panel that
the current shareholders of CiiTECH ("Concert Party") will be regarded as
acting in concert. The holders of convertible loan notes issued by CiiTECH
("CLN Holders") will, if the Intended Acquisition proceeds, convert their
convertible loan notes into shares in CiiTECH and these shares will be sold to
the Company at completion of the Intended Acquisition. The Company has
agreed with the Takeover Panel that the CLN Holders should not be considered
to be members of the Concert Party as they are not connected to the current
shareholders of the CiiTECH.
For the purposes of the Takeover Code, the Concert Party will, immediately
following Admission based on the anticipated raise of £3 million raised at
2p, hold in aggregate, 333,333,333 Shares, representing approximately 47.01
per cent. of the share capital as enlarged by the shares issued pursuant to
the Intended Acquisition, the Placing and shares issued in connection with
Admission ("Enlarged Share Capital").
At the point of Re-domiciliation, the Company will move its registered office
from the British Virgin Islands to Guernsey. The Intended Acquisition will
take place following the Re-domiciliation and so the Company will be subject
to the Code at the time the Company completes the Intended Acquisition and
issues Ordinary Shares to the Concert Party ("Consideration Shares") in
consideration for the Intended Acquisition. Under Rule 9.1 of Takeover Code,
as the Concert Party is acquiring through the issue of the Consideration
Shares an interest in Ordinary Shares which carry 30% or more of the voting
rights of the Company. This would trigger a general offer obligation unless
consent of the Panel is obtained. The Takeover Code contains a procedure
pursuant to which the Panel may waive the obligation to make a general offer
under Rule 9 of the Takeover Code where this obligation would arise as a
result of an issue of new shares. This waiver is subject to, inter alia,
approval of the waiver by an independent vote of shareholders.
The Panel has agreed in this instance to grant a dispensation from the
requirement for a mandatory offer to made under Rule 9.1 of the Takeover Code
as a result of the issue of the Consideration Shares to the Concert Party
without the approval of independent shareholders being obtained on the basis
of the disclosure of the Concert Party's position in this document and in the
Prospectus, as set out below.
Based on a Proposed Purchase Price of £9,667,944, a Proposed Issue Price of
2p and anticipated fundraise of £3 million at 2p, the Concert Party's
expected holdings in the Company following completion of the Intended
Acquisition are detailed below:
Name of Concert Party member Number of Ordinary Shares held on completion of the Intended Acquisition* Percentage of Enlarged Issued Share Capital* Number of Options held on completion of the Intended Acquisition* Maximum number of Ordinary Shares held on completion of the Intended Percentage of Enlarged Fully diluted Issued Share Capital as at Admission**
Acquisition
Clifton Flack 122,117,249 17.2% Nil 122,117,249 15.2%
Yoad Development and Technology 2014 Ltd 70,272,426 9.9% Nil 70,272,426 8.7%
Samuel Jeremy Kattan 33,939,794 4.8% Nil 33,939,794 4.2%
Daniel Nicholas Kattan 33,912,290 4.8% Nil 33,912,290 4.2%
James Adam Kattan 33,939,794 4.8% Nil 33,939,794 4.2%
Benjamin Stern 18,152,564 2.6% Nil 18,152,564 2.3%
Steve Graubart 18,152,564 2.6% Nil 18,152,564 2.3%
Nava Swersky Sofer 1,897,768 0.3% Nil 1,897,768 0.2%
Jonathan Adelman 948,884 0.1% Nil 948,884 0.1%
Total 333,333,333 47.01% Nil 333,333,333 41.3%
*This is based on a Proposed Purchase Price of £9,667,944, a Proposed Issue
Price of 2p and anticipated fundraise of £3 million and may change dependent
upon the finalised terms for the Placing and Intended Acquisition. Although
the members of the Concert Party do not currently hold any Ordinary Shares
they will on the assumptions as aforesaid on Admission hold 333,333,333
Ordinary Shares.
** Assumes exercise in full of all options and warrants expected to be granted
at Admission assuming no other changes to the Company's Enlarged Share
Capital.
Rule 9 of the Takeover Code provides that when any person, together with
persons acting in concert with him, is interested in shares which, in
aggregate, carry 30 per cent. or more of the voting rights of such company but
does not hold share carrying more than 50 per cent. of such voting rights, a
general offer will normally be required if any further interest in shares is
acquired which increases the percentage of shares carrying voting rights in
which he together with persons acting in concert with him, are interested.
Based on the scenario in the above table the Concert Party will be unable to
acquire an interest in shares which would increase the percentage of shares in
the Company carrying voting rights that it is interested without triggering an
obligation to make a general offer under Rule 9.1 of the Takeover Code.
In the event that the marketing of the Placing is more successful, and the
Proposed Issue Price is 3.85p and £3m of new money is raised at that price,
CiiTECH will have a valuation of £15,834,610. In this scenario the Concert
Party's expected holdings in the Company following completion of the Intended
Acquisition are detailed below:
Name of Concert Party member Number of Ordinary Shares held on completion of the Intended Acquisition* Percentage of Enlarged Issued Share Capital* Number of Options held on completion of the Intended Acquisition* Maximum number of Ordinary Shares held on completion of the Intended Percentage of Enlarged Fully diluted Issued Share Capital as at Admission**
Acquisition
Clifton Flack 122,117,249 21.8% Nil 122,117,249 19.1%
Yoad Development and Technology 2014 Ltd 70,272,426 12.6% Nil 70,272,426 11%
Samuel Jeremy Kattan 33,939,794 6.1% Nil 33,939,794 5.3%
Daniel Nicholas Kattan 33,912,290 6.1% Nil 33,912,290 5.3%
James Adam Kattan 33,939,794 6.1% Nil 33,939,794 5.3%
Benjamin Stern 18,152,564 3.2% Nil 18,152,564 2.8%
Steve Graubart 18,152,564 3.2% Nil 18,152,564 2.8%
Nava Swersky Sofer 1,897,768 0.3% Nil 1,897,768 0.3%
Jonathan Adelman 948,884 0.2% Nil 948,884 0.1%
Total 333,333,333 59.57% Nil 333,333,333 52%
*This is based on a Proposed Purchase Price of £15,834,610, a Proposed Issue
Price of 3.85p and anticipated fundraise of £3 million and may change
dependent upon the finalised terms for the Placing and Intended Acquisition.
Although the members of the Concert Party do not currently hold any Ordinary
Shares they will on the assumptions as aforesaid on Admission hold 333,333,333
Ordinary Shares.
** Assumes exercise in full of all options and warrants expected to be granted
at Admission assuming no other changes to the Company's Enlarged Share
Capital.
In the scenario set out in the table above, the members of the Concert Party
would, in aggregate hold Ordinary Shares carrying more than 50 per cent. of
the voting rights of the enlarged issued share capital of the Company on
Admission. Therefore, in this scenario for so long as they continue to be
treated as acting in concert and they continue to hold shares carrying over 50
per cent of the voting rights, the members of the Concert Party will be
entitled to increase their aggregate interest in the voting rights of the
Company without incurring an obligation under Rule 9 of the Takeover Code to
make a general offer. However, individual members of the Concert Party will
not be able to increase their percentage interests in Ordinary Shares through
or between a Rule 9 threshold without Takeover Panel consent.
Further information on the members of the Concert Party is set out below:
1. Clifton Flack is the CEO of CiiTECH. Clifton founded
CiiTECH in 2017 after a 25 year marketing career, with roles including Head of
Global at McCann Universal Search, a digital division of McCann Erickson
Israel, responsible for strategic planning and management of International
clients (2013-2014). In 2015 Clifton co-founded and was Chief Marketing
Officer at iCAN Israel Cannabis, an Israeli innovation ecosystem including a
global industry event 'CannaTech'. Clifton studied marketing and business at
Leeds and Brighton Universities.
2. Yoad Development and Technology 2014 Ltd ("Yoad") is a
private company organised under the laws of the State of Israel with company
number 515093896 and whose registered offices is at 8 Ha'lrus St, Binyamina,
Israel. Yoad formerly provided marketing services to CiiTECH.
3. James Adam Kattan, Samuel Jeremy Kattan and Daniel Nicholas
Kattan are all brothers. James and Daniel are based in the UK and Samuel is
based in Israel. They were initial investors in CiiTECH. Daniel Nicholas
Kattan is a property investor. James Adam Kattan and Samuel Jeremy Kattan are
self-employed.
4. Steve Graubart is the CFO of CiiTECH. Steven Graubart, CFA,
has diversified experience as a CFO and cofounder and as a consultant and
investor across a range of sectors, specifically in regulated sectors,
including in the cannabis, infrastructure, education, fintech and health
sectors. Mr. Graubart started his career as a management consultant with IPAC,
Inc. and Ernst & Young, specializing in working with clients on their
international expansion. He graduated from the Fletcher School of Law and
Diplomacy and SUNY, Stony Brook;
5. Benjamin Stern was a co-founder of CiiTECH and until
October 2021 was COO of CiiTECH. Benjamin has experience in high risk
regulated sectors including fintech industries. We understand Benjamin no
longer has any executive, managerial or operational involvement in CiiTECH;
6. Nava Swersky Sofer leads the board of CiiTECH. She is a
seasoned senior executive and non-executive board member with a diverse,
increasingly progressive, cross sector background, acquired over 30 years of
international business experience in Europe, the US, Canada, Israel, and Asia;
and
7. Jonathan Adelman is the brother-in-law of Clifton Flack and
has been engaged by CiiTECH as a consultant advising CiiTECH in respect of its
corporate governance requirements. He has agreed to be appointed as a
non-executive director of the Company with effect from Admission. He has more
than 25 years of experience as a lawyer in the City of London and as General
Counsel & Company Secretary of various FTSE listed businesses. He is
therefore well placed to assist the board in ensuring the Enlarged Group
complies with its regulatory requirements.
Directors Interests in the Intended Acquisition
None of the Directors of the Company have an interest in CiiTECH. However,
if the Intended Acquisition proceeds, Stonedale Management and Investments
Limited (being a company under the control of a Director, Simon Retter) will
receive 5,500,000 Ordinary Shares in the Company as well as warrants over
5,000,000 Ordinary Shares 1 (#_ftn1) which shall be exercisable at the
Proposed Issue Price in consideration for consultancy services provided in
respect of the Intended Acquisition to the Company.
Daniel Reshef joined the board prior to the LOI being signed the Company.
Under the terms of his engagement he is entitled to a cash payment of £35,000
upon completion of the Intended Acquisition to reflect the additional work
required to close the Intended Acquisition.
Furthermore, the Company on 10 November 2021 agreed that a cash payment of
£35,000 would be made on the same terms to Richard Samuel. The board have
considered the deal related payments for Daniel Reshef and Richard Samuel and
do not regard them as sufficient given their levels of personal wealth to
create a conflict of interest.
Responsibility Statement
All of the directors of the Company being Simon Retter, Mahesh s/o Pulandaran,
Richard Samuel and Daniel Reshef, accept responsibility for the information
contained in this document in respect of the Company and for statements of
opinion made in respect of CiiTECH and the Intended Acquisition and the
recommendations made in this document. However, the statements made in
Appendix 1 are based upon information that has been supplied by CiiTECH as
part of the Admission process which the directors have sought to independently
verify. A number of these statements relate to the current and future
conduct of the CiiTECH business and so relate to matters outside of the
Directors' knowledge and/or control. This information has been included in
this document to provide shareholders with a board overview of the CiiTECH
business rather than provide specific information on which an investment
decision can be made. This document is not intended to act as invitation to
invest in the Company or CiiTECH. Shareholders who wish to learn more about
the Intended Acquisition should contact the Company's broker Optiva Securities
Limited.
To the best of the knowledge and belief of the directors (who have taken all
reasonable care to ensure that such is the case), subject to the qualification
above, the information contained in this document for which they are
responsible is in accordance with the facts and does not omit anything likely
to affect the import of that information.
Approval of Accounts
The Company due to COVID 19 did not hold an Annual General meeting last year
and so has tabled the accounts for the year to 31 March 2020 and the year to
31 March 2021 for approval by shareholders.
Retirement by Rotation
Article 8.5 of the Current Articles Retirement by Rotation. Simon Retter and
Mahesh s/o Pulandaran were both re-elected at the Company's last AGM on 19
December 2019. As the Company held no AGM last year Richard Samuel and
Daniel Reshef decided to both retire by rotation at the AGM and offer
themselves up for re-election.
Business of the AGM
Resolution 1 - Receiving and adopting the Annual Report and Accounts 31March
2020
The Board of Directors of the Company (the "Board") recommends the receiving
and adopting of the annual report and accounts of the Company for the
financial period ended 31 March 2020, together with the directors' report and
the auditor's report be received and adopted.
Resolution 2 - Receiving and adopting the Annual Report and Accounts 31March
2021
The Board of Directors of the Company (the "Board") recommends the receiving
and adopting of the annual report and accounts of the Company for the
financial period ended 31 March 2021, together with the directors' report and
the auditor's report be received and adopted.
Resolutions 3 - Auditor's Appointment and Remuneration
This Resolution proposes the retrospective approval of the appointment of
Crowe U.K. LLP as the Auditors of the Company for the accounts for the year to
31 March 2021 ("2021 Accounts") and authorise the Directors to fix the
Auditors' remuneration. It is usual business for the AGM.
Resolution 4 - Re-election of Richard Samuel as a Director of the Company
To re-elect Richard Samuel as a Director of the Company who has retired by
rotation.
Resolution 5 - Re-election of Daniel Reshef as a Director of the Company
To re-elect Daniel Reshef as a Director of the Company who has retired by
rotation.
Resolutions 6 - Remuneration of Directors of the Company
This Resolution relates to the retrospective approval for the Directors
remuneration as set out in the 2021 Accounts and to approve authority of the
Board to determine the remuneration of the Directors for the year to 31 March
2022. It is usual business for the AGM.
Resolution 7 - Approval of the Intended Acquisition
Resolution 7 proposes that the Intended Acquisition be approved provided that
the Proposed Purchase Price of £15,834,610 is not exceeded.
Resolution 8 - Approval of the change of the Name of the Company
Resolution 8 proposes that the if the Intended Acquisition completes that the
Company name be changed to CiiTECH Group Limited.
Resolution 9 - Authority to Buy-Back Shares
For the purposes of the New Articles, Resolution 9 proposes that the Board be
authorised to make market acquisitions of shares in the capital of the Company
on the terms as more particularly set out in Resolution 9 in the Notice.
Resolution 10 - Directors' Authority to Allot Shares
This is a 75% resolution of shareholders to grant the Board with authority to
allot and issue shares and grant rights to subscribe for shares in the Company
up to a maximum of 1,559,808,922 shares, calculated as follows:
1. up to 483,400,000 of shares in the Company to be issued in
connection with the consideration for the Intended Acquisition;
2. up to 150,000,000 shares, in respect of the Placing;
3. up to 18,931,541 of shares in respect of costs of and
matters related to the Intended Acquisition more detailed particulars of which
will be set out in the Prospectus;
4. up to 23,523,964 shares, in respect of the grant of options
over shares in the Company to directors, employees and consultants to the
Company and its group under a share option plan adopted on or about Admission
provided that authority to allot shares pursuant to this authority shall be
limited to such amount as to ensure that the Company does not allot shares
that represent more than 10% of the issued ordinary share capital of the
Company in any rolling 10 year period;
5. up to 72,945,077 of shares in respect of the conversion of
the loan notes, exercise of options and warrants other than those granted
under an employee share scheme; and
6. otherwise than pursuant to paragraphs (i) to (v)above,
811,011,154 shares (being 100% of the fully diluted, issued shares of the
Company as at Admission) for such other purposes as the directors consider
necessary or appropriate.
PROVIDED that this power shall expire on the conclusion of the next annual
general meeting of the Company (unless renewed, varied or revoked by the
Company prior to or on that date) save that the Company may, before such
expiry, make offer(s) or agreement(s) which would or might require Ordinary
Shares to be allotted after such expiry and the Directors may allot Ordinary
Shares in pursuance of any such offers or agreements notwithstanding that the
power conferred by this resolution has expired.
Resolution 11 - Waiver of Pre-emption Rights
This is a 75% resolution of shareholders, and a special resolution for the
purposes of the New Articles, to authorize the directors to allot and issue
the shares which are the subject of Resolution 10 free of the rights of
pre-emption set out in the New Articles, on the terms as more particularly set
out in Resolution 13 in the Notice.
Resolution 12 - Re-domiciliation of the Company to Guernsey
The Company be re-domiciled from British Virgin Islands ("BVI") to Guernsey
including in accordance with BVI law, the transfer of registered office of the
Company from the BVI to Guernsey and for this re-domiciliation to take effect
before the Intended Acquisition. This resolution is proposed as a special
resolution.
Resolution 13 - the New Articles
In addition, to effect the Re-domiciliation, the Company will also require a
75% resolution to be passed approving the adoption of a New Articles in
accordance with Guernsey law upon completion of the Re-domiciliation.
Resolution 13 proposes to approve the adoption of the New Articles which will
be effective upon the Re-Domiciliation.
For the avoidance of doubt, Resolutions 12 and 13 (together the
"Re-domiciliation Resolutions") will be contingent on the passing of the other
Re-domiciliation Resolution, such that both Re-domiciliation Resolutions will
be passed or none will be passed.
A copy of the proposed New Articles is attached in Appendix 4 and available
from the Company's website at www.fragrantprosperityholdings.com.
In producing the New Articles, the Directors have ensured that as far as
possible as a matter of Guernsey law, all of the substantive provisions of the
Current Articles relating to the rights of shareholders and their ability to
transfer shares have been retained in the New Articles.
A summary of the material differences between the Current Articles and the New
Articles is enclosed in Appendix 3. However, shareholders are advised to
review the New Articles in their entirety, and not to rely on the summary.
Recommendation
The Board believes that the resolutions to be put to the AGM are in the best
interests of shareholders as a whole and, accordingly, recommends that
shareholders vote in favour of the resolutions.
Forms of Proxy and Forms of Instruction
A Form of Proxy and a Form of Instruction for use at the AGM are enclosed with
this letter.
If you are a holder of Ordinary Shares in FPP in certificated form, you are
asked to complete and sign the enclosed Form of Proxy and return it to the
Computershare Investor Services (BVI) Limited c/o The Pavilions Bridgwater
Road Bristol BS99 6ZY United Kingdom either by post or courier, and by email
#ukcsbrs.externalproxyqueries@computershare.co.uk
(mailto:#ukcsbrs.externalproxyqueries@computershare.co.uk)
mailto:info@valeig.com (mailto:info@valeig.com) so as to arrive no later
than 48 hours before the time fixed for the AGM which is Hill Dickinson LLP,
The Broadgate Tower, 20 Primrose St, London EC2A 2EW at 10 a.m. GMT on 13
January 2022. The return of a Form of Proxy will not, however, prevent you
from attending the AGM and voting, in person, should you wish to do so.
If you are a holder of depositary interests representing Ordinary Shares in
the Company ("Depositary Interests"), you are asked to complete and sign the
enclosed Form of Instruction and return it to Computershare Investor Services
PLC, The Pavilions, Bridgwater Road, Bristol BS99 6ZY, United Kingdom, either
by post or courier, and by email
#ukcsbrs.externalproxyqueries@computershare.co.uk
(mailto:#ukcsbrs.externalproxyqueries@computershare.co.uk) so as to arrive no
later than 72 hours before the time fixed for the AGM which is Hill Dickinson
LLP, The Broadgate Tower, 20 Primrose St, London EC2A 2EW at 10 a.m. GMT on 13
January 2022.
Depositary Interest holders wishing to attend the AGM should request a Letter
of Representation by contacting the depositary at Computershare Investor
Services PLC, The Pavilions, Bridgwater Road, Bristol BS99 6ZY, United Kingdom
or by email !ukallditeam2@computershare.co.uk by no later than at 10 a.m.
GMT on 10 January 2022.
Yours faithfully,
Simon Retter
Chairman
for and on behalf of the Board of Directors of Fragrant Prosperity Holdings
Limited
Fragrant Prosperity Holdings Limited
(Incorporated in British Virgin Islands under the BVI Business Companies Act,
2004 (as amended) with registered number 1905051)
NOTICE OF 2021 ANNUAL GENERAL MEETING
NOTICE IS HEREBY GIVEN THAT the 2021 Annual General Meeting of Fragrant
Prosperity Holdings Limited ("FPP" or the "Company") will be held at Hill
Dickinson LLP, The Broadgate Tower, 20 Primrose St, London EC2A 2EW at 10 a.m.
GMT on 13 January 2022 (the "AGM") for the purposes of considering and, if
thought fit, approving the following resolutions:
RESOLUTIONS
1. Annual Report and Accounts, Directors' Report and
Auditor's Report of the Company
THAT the Annual Report and Accounts of the Company for the financial period
ended 31 March 2020, together with the Directors' Report and the Auditor's
Report be received and adopted.
2. Annual Report and Accounts, Directors' Report and
Auditor's Report of the Company
THAT the Annual Report and Accounts of the Company for the financial period
ended 31 March 2021, together with the Directors' Report and the Auditor's
Report be received and adopted.
3. Re-appointment and Remuneration of Auditors of the
Company
THAT Crowe U.K. LLP be retrospectively appointed as the Auditors of the
Company for the accounts for the year to 2021 Accounts and authorise the
Directors to fix the Auditors' remuneration.
4. Resolution 4 - Re-election of Richard Samuel as
a Director of the Company
THAT Richard Samuel be re-elected as a Director of the Company.
5. Resolution 5 - Re-election of Daniel Reshef as
a Director of the Company
THAT Daniel Reshef be re-elected as a Director of the Company.
6. Remuneration of Directors of the Company
THAT the Directors remuneration as set out in the 2021 Accounts be
retrospectively approved and the Board be granted authority to determine the
Directors' remuneration and other emoluments and benefits until the conclusion
of the next annual general meeting.
7. Approval of the Intended Acquisition
THAT the Intended Acquisition be approved provided that the Proposed Purchase
Price of £15,834,610 is not exceeded.
8. Change of the Name of the Company
THAT, if the Intended Acquisition completes, the Company name be changed to
CiiTECH Group Limited.
9. Directors Authority to Make Market Purchases
THAT, the Company is generally and unconditionally authorized to make market
purchases of ordinary shares in the capital of the Company on such terms and
in such manner (and with respect to those shares cancel them or hold them as
treasury shares) as the directors shall determine provided that:
1. the maximum number of ordinary shares hereby authorised to
be purchased is limited to such number of ordinary shares as represents 10% of
the issued share capital of the Company on a fully diluted basis as of the
date this resolution is passed;
2. here shall be no minimum price;
3. purchase on any trading day more than 25 % of the average
daily volume of the shares on the trading venue on which the purchase is
carried out. and
4. the maximum price, exclusive of associated expenses, which
may be paid for an ordinary shares shall not be more than an amount equal to 5
per cent. of the average of the middle market quotations for an ordinary share
derived from the London Stock Exchange Daily Official List for the five
business days immediately preceding the date on which such ordinary share is
contracted to be purchased,
such authorities to apply in substitution for all previous authorities and to
expire on the date occurring 15 months from the date of the passing of this
resolution or, if earlier, on the conclusion of the Company's next annual
general meeting but, in each case, so that the Company may make any offer or
agreement before such expiry to purchase ordinary shares under this authority
which will or may be completed wholly or partly after the expiry of such
authority and may make a purchase of ordinary shares in pursuance of any such
offer or agreement notwithstanding that the authorities conferred by this
resolution have expired.
5. Directors' Authority to Allot Shares
THAT the Directors be and are hereby generally and unconditionally authorised
to exercise all powers of the Company to allot Ordinary Shares up to a maximum
of 1,559,808,922 Ordinary Shares, calculated as follows:
1. up to 483,400,000 of shares in the Company to be
issued in connection with the consideration for the Intended Acquisition;
2. up to 150,000,000 shares, in respect of the Placing;
3. up to 18,931,541 of shares in respect of costs of and
matters related to the Intended Acquisition more detailed particulars of which
will be set out in the Prospectus;
4. up to 23,523,964 shares, in respect of the grant of
options over shares in the Company to directors, employees and consultants to
the Company and its group under a share option plan adopted on or about
Admission provided that authority to allot shares pursuant to this authority
shall be limited to such amount as to ensure that the Company does not allot
shares that represent more than 10% of the issued ordinary share capital of
the Company in any rolling 10 year period;
5. up to 72,945,077 of shares in respect of the
conversion of the loan notes, exercise of options and warrants other than
those granted under an employee share scheme; and
6. otherwise than pursuant to paragraphs (i) to
(v)above, 811,011,154 shares (being 100% of the fully diluted, issued shares
of the Company as at Admission) for such other purposes as the directors
consider necessary or appropriate.
PROVIDED that this power shall expire on the conclusion of the next Annual
General Meeting of the Company (unless renewed, varied or revoked by the
Company prior to or on that date) save that the Company may, before such
expiry, make offer(s) or agreement(s) which would or might require Ordinary
Shares to be allotted after such expiry and the Directors may allot Ordinary
Shares in pursuance of any such offers or agreements notwithstanding that the
power conferred by this resolution has expired. This resolution is proposed
as a special resolution.
7. Waiver of Pre-Emption Rights
This resolution is proposed as a special resolution for the purposes of the
new articles of incorporation of the Company proposed to be adopted by way of
Resolution 13, below ("New Articles").
That the directors are generally and unconditionally authorised (including for
the purposes of article 5.7 of the New Articles) to issue Equity Securities
(as defined in the New Articles) for cash pursuant to the authority conferred
on them by resolution 10, above, as if any shareholder rights of pre-emption
(including, without limitation, under Article 5.2 of the New Articles) did not
apply, and such authority shall expire when the authority conferred on the
directors by resolution 10, above, expires save that, before the expiry of
this power, the Company may make any offer or agreement which would or might
require Equity Securities to be issued as if any such rights of pre-emption
did not apply after such expiry and the directors may issue Equity Securities
in pursuance of such offer or agreement as if such rights of pre-emption did
not apply notwithstanding that the authorities conferred by this resolution
have expired.
8. Re-domiciliation of the Company to Guernsey
THAT conditional upon passing resolution 7 and the Company entering into
definitive agreements in respect of the Intended Acquisition (as defined in
the Letter from the Chairman) the directors be authorised to apply for the
Company to be re-domiciled from the British Virgin Islands ("BVI") to Guernsey
("Re-domiciliation") and that, in accordance with BVI law, the registered
office of the Company be transferred from the BVI to Guernsey. This
resolution is proposed as a special resolution.
9. New Articles
THAT, subject to and with effect from the date of the issue of the Guernsey
certificate of registration in respect of the Company, the new Guernsey law
governed memorandum and articles of incorporation of the Company, a copy of
which is contained in Appendix 4 to this Notice being the New Articles be and
are adopted in substitution for, and in replacement of, the existing
memorandum and articles of association of the Company and subject to the
authorities granted to by the shareholders pursuant to Resolutions 7, 8, 10,
11 and 12 above.
Simon Retter, Chairman
by order of the Board, 15 December 2021
Registered Office
Vistra Corporate Services Centre
Wickhams Cay II, Road Town,
Tortola, VG1110
British Virgin Islands
Appendix 1 - Summary of CiiTECH
CiiTECH is a UK incorporated company which acts as the holding company for the
CiiTECH Group, a group focused on the development of a portfolio of
cannabidiol (CBD) wellness and tetrahydrocannabidiol (THC) Medicinal Cannabis
branded products. CiiTECH initially focused its efforts on the UK CBD wellness
market with UK sales representing approximately 95% of its turnover in FY
2020, but has now established distribution relationships in Brazil, Israel and
South Africa.
CiiTECH has created a compelling house of brands:
1. Provacan: CiiTECH's flagship brand in the UK, this is
available in many forms including as ingestibles (tinctures, capsules and
gummies), dermatologicals (cosmetics, topicals) and vapors (e-liquids and
extracts). It was developed and designed to give the consumer confidence that
Provacan is "safe and effective", not "fun and funky."
2. IMPACT: IMPACT providing CBD support for fitness and
impact sports. Launched in partnership with two rugby players, IMPACT is
intended to become CiiTECH's flagship brand in South Africa as a part of its
go-to-market strategy around rugby academies and sports institutes.
3. HüGG: HüGG is a CBD self-care and beauty brand for
women of all ages. It was built around a range of well-proven cosmetic
ingredients to create a trustworthy, high-quality CBD cosmetics brand.
4. ProPaws (in development): CiiTECH is working with one
of its key manufacturing partners to create a pet care range of cannabis-based
healthcare products.
5. Labotanix (in development): Labotanix is being
developed as a value brand to supply marketplace partners as a complement to
CiiTECH's premium brands.
The key territories that CiiTECH operates in are as follows:
6. UK: The UK is CiiTECH's key market and one in which
all CiiTECH's live CBD branded products are currently sold. Using the
credibility of the UK's pharmaceutical market globally, CiiTECH uses the UK as
its market testing, launch and proof of concept base from which brands are
then launched into other jurisdictions. The core revenue stream in the UK is
through its flagship brand Provacan. Moving forward, CiiTECH's marketing
budget will be focused on building its CBD wellness market share and rolling
out its THC Medicinal Cannabis products.
7. Brazil: CiiTECH currently distributes Provacan CBD
products under the Compassionate Use programme in Brazil. Moving forward the
Enlarged Group plans to apply for Sanitary Authorisation from ANVISA for a
range of Provacan-branded CBD products and is aiming to introduce THC
Medicinal Cannabis products under the ANVISA Compassionate Use programme if
registration with ANVISA can be obtained.
8. Israel: CBD wellness products cannot currently be
sold in Israel without a licence from the local regulator. Nonetheless
CiiTECH has signed an agreement with Ecolife, a licenced importer, to
distribute its CBD wellness brands in Israel when the law changes in Israel to
permit such products to be sold over the counter. CiiTECH is also currently
developing a range of Provacan-branded Medicinal Cannabis products which it
intends to market locally with Cannassure Ltd.
Through its joint venture with the Yissum Research Development Company of the
Hebrew University of Jerusalem Ltd (Yissum), CiiTECH has been engaged in
R&D projects for the treatment of non-alcohol related fatty liver disease
(NAFLD), diabetes and obesity. Two pre-clinical studies have been funded by
CiiTECH, the first in 2017 and the second in 2020. The research resulted in
the patent application for CBD/CBG to treat NAFLD, diabetes and obesity.
Separately in 2017 CiiTECH funded a study to investigate the potential for CBD
to treat asthma.
9. South Africa: CiiTECH's operations in this territory
are carried out through its wholly owned subsidiary, CiiTECH SA (pty) Ltd.
CiiTECH will market its CBD wellness products in South Africa. CiiTECH plans
to use its strong rugby partnerships and networks to market its IMPACT CBD
brand as its flagship brand in South Africa.
CiiTECH has also established a distribution agreement with a third party to
exclusively distribute its HüGG branded products in South Africa. CiiTECH
is currently exploring opportunities to appoint local manufacturing,
warehousing and order fulfilment partners.
As indicated above, the Enlarged Group's strategy is as follows:
1. To increase brand awareness and sales of its full
range of CBD wellness products in the UK and launch its unlicensed THC
Medicinal Cannabis products in the UK;
2. To grow sales in Brazil of CBD wellness products and
launch Provacan-branded Medicinal Cannabis products;
3. To launch a range of CBD wellness over the counter
products in Israel as soon as a change in law permits and to launch
Provacan-branded THC Medicinal Cannabis products under licence in Israel;
4. To launch its IMPACT sports and HuGG cosmetics CBD
wellness brands in South Africa;
and
5. To advance its R&D activities in Israel in
partnership with Yissum.
1 These share numbers assume a 2p Proposed Issue Price
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NOADKABQBBDKCBDRecent news on Fragrant Prosperity Holdings
See all newsREG - Fragrant Prosperity - Holding(s) in Company
AnnouncementREG - Fragrant Prosperity - Holding(s) in Company
AnnouncementREG - Fragrant Prosperity - Holding(s) in Company
AnnouncementREG - Fragrant Prosperity - Issue of Equity
AnnouncementREG - Fragrant Prosperity - Appointment to Investment Advisory Board
Announcement